vs
Cardio Diagnostics Holdings, Inc.（CDIO）与Lantheus Holdings, Inc.（LNTH）财务数据对比。点击上方公司名可切换其他公司
Lantheus Holdings, Inc.的季度营收约是Cardio Diagnostics Holdings, Inc.的114426.4倍（$406.8M vs $3.6K）。Lantheus Holdings, Inc.同比增速更快（4.0% vs -21.2%）。Lantheus Holdings, Inc.自由现金流更多（$81.4M vs $-5.9M）。过去两年Lantheus Holdings, Inc.的营收复合增速更高（4.9% vs -52.8%）
Cardio Diagnostics Holdings, Inc.是一家专注于精准心血管医疗的企业，开发并商业化整合遗传与表观遗传技术的诊断检测产品，可早期识别冠心病、心力衰竭等心血管疾病，主要服务美国市场的医疗机构、临床实验室与患者。
Lantheus Holdings是一家全球性医疗保健企业，专注于研发、生产及商业化创新诊断显像剂与相关解决方案，产品覆盖肿瘤学、心脏病学、泌尿学等核心医疗领域，主要市场遍及北美及全球其他重点地区。
CDIO vs LNTH — 直观对比
营收规模更大
LNTH
是对方的114426.4倍
$3.6K
营收增速更快
LNTH
高出25.2%
-21.2%
自由现金流更多
LNTH
多$87.3M
$-5.9M
两年增速更快
LNTH
近两年复合增速
-52.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6K | $406.8M |
| 净利润 | — | $54.1M |
| 毛利率 | — | 59.2% |
| 营业利润率 | — | 19.0% |
| 净利率 | — | 13.3% |
| 营收同比 | -21.2% | 4.0% |
| 净利润同比 | 3.6% | 558.8% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDIOLNTH
| Q4 25 | $3.6K | $406.8M | ||
| Q3 25 | $2.9K | $384.0M | ||
| Q2 25 | $7.5K | $378.0M | ||
| Q1 25 | $940 | $372.8M | ||
| Q4 24 | $4.5K | $391.1M | ||
| Q3 24 | $6.6K | $378.7M | ||
| Q2 24 | $7.9K | $394.1M | ||
| Q1 24 | $15.9K | $370.0M |
净利润CDIOLNTH
| Q4 25 | — | $54.1M | ||
| Q3 25 | $-1.7M | $27.8M | ||
| Q2 25 | $-1.7M | $78.8M | ||
| Q1 25 | $-1.6M | $72.9M | ||
| Q4 24 | — | $-11.8M | ||
| Q3 24 | $-1.4M | $131.1M | ||
| Q2 24 | $-1.3M | $62.1M | ||
| Q1 24 | $-4.2M | $131.1M |
毛利率CDIOLNTH
| Q4 25 | — | 59.2% | ||
| Q3 25 | — | 57.9% | ||
| Q2 25 | — | 63.8% | ||
| Q1 25 | — | 63.8% | ||
| Q4 24 | — | 63.5% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 65.4% |
营业利润率CDIOLNTH
| Q4 25 | — | 19.0% | ||
| Q3 25 | -59950.9% | 11.4% | ||
| Q2 25 | -22457.5% | 23.3% | ||
| Q1 25 | -173463.8% | 27.4% | ||
| Q4 24 | — | 29.1% | ||
| Q3 24 | -21412.9% | 35.3% | ||
| Q2 24 | -16295.6% | 26.1% | ||
| Q1 24 | -26105.3% | 28.8% |
净利率CDIOLNTH
| Q4 25 | — | 13.3% | ||
| Q3 25 | -60053.8% | 7.2% | ||
| Q2 25 | -22517.7% | 20.8% | ||
| Q1 25 | -173943.0% | 19.6% | ||
| Q4 24 | — | -3.0% | ||
| Q3 24 | -21467.6% | 34.6% | ||
| Q2 24 | -16365.9% | 15.8% | ||
| Q1 24 | -26140.0% | 35.4% |
每股收益（稀释后）CDIOLNTH
| Q4 25 | — | $0.86 | ||
| Q3 25 | $-0.98 | $0.41 | ||
| Q2 25 | $-0.97 | $1.12 | ||
| Q1 25 | $-0.97 | $1.02 | ||
| Q4 24 | — | $-0.18 | ||
| Q3 24 | $-1.73 | $1.79 | ||
| Q2 24 | $-1.71 | $0.88 | ||
| Q1 24 | $-5.93 | $1.87 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $359.1M |
| 总债务越低越好 | — | $568.7M |
| 股东权益账面价值 | $7.0M | $1.1B |
| 总资产 | $7.8M | $2.2B |
| 负债/权益比越低杠杆越低 | — | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资CDIOLNTH
| Q4 25 | — | $359.1M | ||
| Q3 25 | — | $382.0M | ||
| Q2 25 | — | $695.6M | ||
| Q1 25 | — | $938.5M | ||
| Q4 24 | — | $912.8M | ||
| Q3 24 | — | $866.4M | ||
| Q2 24 | — | $757.0M | ||
| Q1 24 | — | $718.3M |
总债务CDIOLNTH
| Q4 25 | — | $568.7M | ||
| Q3 25 | — | $567.9M | ||
| Q2 25 | — | $566.8M | ||
| Q1 25 | — | $566.1M | ||
| Q4 24 | — | $565.3M | ||
| Q3 24 | — | $613.0K | ||
| Q2 24 | — | $563.2M | ||
| Q1 24 | — | $562.5M |
股东权益CDIOLNTH
| Q4 25 | $7.0M | $1.1B | ||
| Q3 25 | $8.2M | $1.1B | ||
| Q2 25 | $9.7M | $1.2B | ||
| Q1 25 | $11.4M | $1.2B | ||
| Q4 24 | $9.6M | $1.1B | ||
| Q3 24 | $3.7M | $1.2B | ||
| Q2 24 | $3.1M | $1.0B | ||
| Q1 24 | $3.0M | $945.5M |
总资产CDIOLNTH
| Q4 25 | $7.8M | $2.2B | ||
| Q3 25 | $8.8M | $2.3B | ||
| Q2 25 | $10.4M | $2.1B | ||
| Q1 25 | $12.3M | $2.1B | ||
| Q4 24 | $10.6M | $2.0B | ||
| Q3 24 | $4.5M | $2.0B | ||
| Q2 24 | $4.0M | $1.9B | ||
| Q1 24 | $4.3M | $1.8B |
负债/权益比CDIOLNTH
| Q4 25 | — | 0.52× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | — | 0.59× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.7M | $90.2M |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | $81.4M |
| 自由现金流率自由现金流/营收 | -166361.5% | 20.0% |
| 资本支出强度资本支出/营收 | 5269.1% | 2.2% |
| 现金转化率经营现金流/净利润 | — | 1.67× |
| 过去12个月自由现金流最近4个季度 | $-10.5M | $354.1M |
8季度趋势，按日历期对齐
经营现金流CDIOLNTH
| Q4 25 | $-5.7M | $90.2M | ||
| Q3 25 | $-1.4M | $105.3M | ||
| Q2 25 | $-1.6M | $87.1M | ||
| Q1 25 | $-1.4M | $107.6M | ||
| Q4 24 | $-5.0M | $157.7M | ||
| Q3 24 | $-1.2M | $175.1M | ||
| Q2 24 | $-1.2M | $84.7M | ||
| Q1 24 | $-1.2M | $127.2M |
自由现金流CDIOLNTH
| Q4 25 | $-5.9M | $81.4M | ||
| Q3 25 | $-1.6M | $94.7M | ||
| Q2 25 | $-1.6M | $79.1M | ||
| Q1 25 | $-1.4M | $98.8M | ||
| Q4 24 | $-5.2M | $141.4M | ||
| Q3 24 | $-1.2M | $159.3M | ||
| Q2 24 | $-1.4M | $73.5M | ||
| Q1 24 | $-1.3M | $119.0M |
自由现金流率CDIOLNTH
| Q4 25 | -166361.5% | 20.0% | ||
| Q3 25 | -54509.7% | 24.7% | ||
| Q2 25 | -21273.1% | 20.9% | ||
| Q1 25 | -149562.6% | 26.5% | ||
| Q4 24 | -115422.6% | 36.1% | ||
| Q3 24 | -17942.3% | 42.0% | ||
| Q2 24 | -17513.3% | 18.7% | ||
| Q1 24 | -7866.9% | 32.2% |
资本支出强度CDIOLNTH
| Q4 25 | 5269.1% | 2.2% | ||
| Q3 25 | 5703.5% | 2.8% | ||
| Q2 25 | 250.1% | 2.1% | ||
| Q1 25 | 615.6% | 2.3% | ||
| Q4 24 | 4759.9% | 4.2% | ||
| Q3 24 | 353.3% | 4.2% | ||
| Q2 24 | 2133.4% | 2.8% | ||
| Q1 24 | 125.5% | 2.2% |
现金转化率CDIOLNTH
| Q4 25 | — | 1.67× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 1.11× | ||
| Q1 25 | — | 1.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 0.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDIO
暂无分部数据
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
